Resources

All Resources

Our resource hub to discover reports, policy papers and other forms of informative content

Filter by

Increasing Access to Innovative Medicines

The impact of the COVID-19 pandemic has shifted the health landscape in Canada. While the federal government has demonstrated its ability to react to an unprecedented health crisis, doing so has also sharpened the focus on domestic capacity and innovation in the life sciences sector.

Throughout the pandemic, we could not be prouder of our members’ collaborative efforts worldwide. From the onset, they worked toward agreements with nations and competitors to increase manufacturing capacity and minimize pharmaceutical supply chain disruption. IMC members demonstrated the industry’s value to the world, as the critical importance of reliable access to medicines was brought into focus.

Learn more | View

Alberta Budget Submission 2023

Innovative Medicines Canada (IMC) is the national association representing Canada’s innovative pharmaceutical industry. The association advocates for policies that promote the discovery, development and delivery of innovative medicines and vaccines to improve the lives of all Canadians. In addition, it supports the commitment of its members as valued partners in the Canadian healthcare system.

The association represents 50 companies, which invest nearly $1.4 billion annually in research and development. In this way, it nurtures a high value-added knowledge economy while contributing $8 billion to the national economy.

Learn more | View

Innovative Agreements Framework

Many products coming to market are poorly served by traditional negotiation approaches. This document describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework.

Learn more | View

Canadian Drug Access Pathway

The process for Canadians to access new medicines is extremely complex and involves several different federal, provincial, and territorial agencies. It takes two years following approval (732 days) for Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days).

Learn more | View

Bluesky Project

Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022

Learn more | View

resources

Discover. Learn.
Understand.

Informative content to keep you up to date on the most pressing issues facing our industry.